Related Experiment Videos
[Hepatitis C virus infection in renal diseases: state of knowledge, therapeutic problems and perspectives]
1Pracowni Dializ Kliniki Chorób Dzieci, Instytut Pediatrii Akademia Medyczna im. Karola Marcinkowskiego w Poznaniu.
Insights
Interferon-alpha therapy may alter T-helper cell balance in dialysis patients with chronic hepatitis C virus (HCV) infection. Understanding this immune response is crucial for improving outcomes in patients with end-stage renal disease (ESRD).
Area of Science:
- Hepatology
- Immunology
- Nephrology
Context:
- Chronic hepatitis C virus (HCV) infection affects millions worldwide, with significant risks of cirrhosis and complications.
- Dialysis patients with end-stage renal disease (ESRD) have a higher prevalence of HCV and a blunted immune response.
- HCV infection in ESRD patients undergoing renal transplantation increases liver disease and mortality risks.
Purpose:
- To evaluate the influence of interferon-alpha (IFN-a) therapy on the T-helper 1 (Th1)/T-helper 2 (Th2) balance in hemodialysis (HD) patients with chronic HCV infection.
- To understand the immunopathogenesis of chronic HCV infection in ESRD patients.
- To explore the potential of modulating Th1/Th2 activity for improved HCV treatment in dialysis patients.
Summary:
- The study investigates the effects of IFN-a therapy on Th1/Th2 cytokine profiles in hemodialysis patients with chronic HCV infection.
- Cytokine patterns secreted by T lymphocytes, specifically Th1 and Th2 cells, determine the immune response against infectious agents.
- Understanding the Th1/Th2 balance is crucial for assessing the immune status of HCV-infected patients, particularly those with ESRD.
Impact:
- Eradicating HCV in ESRD patients may significantly reduce morbidity and mortality in renal allograft recipients.
- This research could lead to better therapeutic strategies for HCV in dialysis patients.
- Findings may enhance our understanding of immune responses in chronic viral infections and transplantation.
Abstract:
Chronic infection with hepatitis C virus (HCV) is estimated to affect almost 170 million individuals worldwide. 20-30% of these individuals develop cirrhosis and its sequelae. Only 15-20% of patients with chronic hepatitis C achieve a sustained virological response to interferon monotherapy. The prevalence of anti-HCV antibodies in dialysis patients varies between 1% and 29% in Western Europe. In patients with ESRD on maintenance HD therapy, in whom a blunted immune response per se is observed, the usefulness of IFN-alpha therapy is usually discussed in the context of subsequent transplantation associated with intensive immunosuppressive treatment regimens. A recent study has shown that in this patient group renal transplantation is associated with a fivefold increase in posttransplantation liver disease as well as a relative risk of death of 3.3 compared to HCV-negative patients. Thus, eradication of HCV infection in patients with ESRD may substantially reduce morbidity and mortality in renal allograft recipients. The imbalance of T-helper (Th) lymphocyte cytokine production may play an important role in the immunopathogenesis of chronic HCV infection. Little is known about the effects of IFN-alpha therapy on Th1/Th2 activity in HD patients. The type of immune response against infectious agents is determined in part by the pattern of cytokines secreted by T lymphocytes. Th1 cells promote cellular immunity against infectious agents, while Th2 cells induce humoral immune response and immune tolerance activity. The measurement of Th1/Th2 profile should increase our understanding of the immune status of patients with HCV infection. Therefore, the recently presented studies were undertaken to evaluate the influence of IFN-a therapy on Th1/Th2 balance in HD patients with chronic HCV infection.